A look at a CDMO’s value throughout a monoclonal antibody (mAb) therapeutic's lifecycle
The growing number of monoclonal antibodies (mAbs), and the maturation of their process development and manufacturing, have led to contract development and manufacturing organizations (CDMOs) playing an increasingly important role in expediting these programs’ path to commercialization. This infographic explores how an experienced biologics CDMO adds value throughout a mAb’s lifecycle.